Global Recombinant FSH Injections Supply, Demand and Key Producers, 2024-2030

Global Recombinant FSH Injections Supply, Demand and Key Producers, 2024-2030

The global Recombinant FSH Injections market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The fertility preservation and infertility treatment market has witnessed significant growth in recent years, driven by factors such as increasing infertility rates, delayed pregnancies, advancements in assisted reproductive technologies (ART), and growing awareness. Fertility preservation technologies, including egg freezing and sperm banking, have gained popularity among individuals seeking to preserve their reproductive potential. In the infertility treatment segment, in vitro fertilization (IVF), intrauterine insemination (IUI), and other ART procedures have become mainstream options. Future developments are anticipated in areas such as personalized medicine, gene editing technologies, and improved success rates in ART procedures. The market is likely to see ongoing advancements, innovations, and collaborations aimed at addressing infertility challenges and expanding the range of options available to individuals and couples.

Follicle Stimulating Hormone (FSH) injections are pharmaceutical preparations containing the hormone FSH, a crucial component in the regulation of reproductive processes. FSH is produced by the pituitary gland and plays a key role in the stimulation of ovarian follicles in females and sperm production in males. FSH injections are commonly used in assisted reproductive technologies, such as in vitro fertilization (IVF), to enhance the development and maturation of multiple follicles in the ovaries. In fertility treatments, these injections help regulate and stimulate the ovaries to produce more eggs, increasing the chances of successful fertilization and pregnancy.

Human follicle stimulating hormone (FSH) includes urinary human follicle stimulating hormone (uFSH) and recombinant FSH (rFSH). According to expert consensus, recombinant follicle-stimulating hormone is available in two dosage forms: powder injection and water injection.

This report studies the global Recombinant FSH Injections production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Recombinant FSH Injections, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Recombinant FSH Injections that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Recombinant FSH Injections total production and demand, 2019-2030, (K Units)

Global Recombinant FSH Injections total production value, 2019-2030, (USD Million)

Global Recombinant FSH Injections production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Recombinant FSH Injections consumption by region & country, CAGR, 2019-2030 & (K Units)

U.S. VS China: Recombinant FSH Injections domestic production, consumption, key domestic manufacturers and share

Global Recombinant FSH Injections production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)

Global Recombinant FSH Injections production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Recombinant FSH Injections production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Recombinant FSH Injections market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gonal-F (Merck), Follistim (Organon), Bravelle (Ferring), Menopur (Ferring), Fostimon (IBSA), Puregon (Organon), BEMFOLA (Gedeon Richter), Follitrope (LG Chem) and GenSci, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Recombinant FSH Injections market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Recombinant FSH Injections Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Recombinant FSH Injections Market, Segmentation by Type
Powder
Liquid

Global Recombinant FSH Injections Market, Segmentation by Application
IVF and Embryo Transfer
Infertility Treatment

Companies Profiled:
Gonal-F (Merck)
Follistim (Organon)
Bravelle (Ferring)
Menopur (Ferring)
Fostimon (IBSA)
Puregon (Organon)
BEMFOLA (Gedeon Richter)
Follitrope (LG Chem)
GenSci

Key Questions Answered

1. How big is the global Recombinant FSH Injections market?

2. What is the demand of the global Recombinant FSH Injections market?

3. What is the year over year growth of the global Recombinant FSH Injections market?

4. What is the production and production value of the global Recombinant FSH Injections market?

5. Who are the key producers in the global Recombinant FSH Injections market?